Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Review
  • Published:

The relationship between hypogonadism and erectile dysfunction

International Journal of Impotence Research volume 20, pages 231–235 (2008)Cite this article

Abstract

It is well known that testosterone enhances sexual interest leading to an increased frequency of sexual acts and an increase in the frequency of sleep-related erections. However, it has little effect on fantasy- or visually induced erections. Exact contribution to erection from testosterone in men remains unclear. Animal studies have well demonstrated that testosterone plays critical physiological (activity of nitric oxide synthases and phosphodiesterases), biochemical (through an endothelial-independent pathway and adrenergic tonicity) and structural (change of fibroelasticity and hollow cell accumulation) roles in erectile function. The supplementation of testosterone to castrated animals can restore erectile function. Clinically, reports of patients with erectile dysfunction (ED) combined with hypogonadism who receive testosterone therapy have inconsistent results. However, testosterone may ameliorate the expression of the phosphodiesterase-5 (PDE5) inhibitor, and the use of testosterone in conjunction with the PDE5 inhibitor revealed convincing results. Because of potential risks in clinical use, testosterone therapy should be individualized, carefully considered and closely monitored, especially, in patients with possible occult prostate cancer, and large benign prostatic hyperplasia. Lower urinary tract symptoms might be worsened by this treatment, since the prostate is an androgen-dependent tissue.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2

Similar content being viewed by others

References

  1. Buvat J, Lemaire A . Endocrine screening in 1022 men with erectile dysfunction: clinical significance and cost-effective strategy. J Urol 1997; 158: 1764–1767.

    Article  CAS  PubMed  Google Scholar 

  2. Feldman HA, Goldstein I, Hatzichristou DG, Krane RJ, McKinlay JB . Impotence and its medical and psychological correlates: results of the Massachusetts Male Aging Study. J Urol 1994; 151: 54–61.

    Article  CAS  PubMed  Google Scholar 

  3. Mulhall JP, Valenzuela R, Aviv N, Parker M . Effect of testosterone supplementation on sexual function in hypogonadal men with erectile dysfunction. Urology 2004; 63: 348–352.

    Article  PubMed  Google Scholar 

  4. Seftel AD, Mark RJ, Secrest AR, Smith TM . Restorative increases in serum testosterone levels are significantly correlated to improvements in sexual functioning. J Androl 2004; 25: 963–972.

    Article  PubMed  Google Scholar 

  5. Aversa A, Isidori AM, De Martino MU, Caprio M, Fabbrini E, Rochietti-March M et al. Androgens and penile erection: evidence for a direct relationship between free testosterone and cavernous vasodilation in men with erectile dysfunction. Clin Endocrinol (Oxf) 2000; 53: 517–522.

    Article  CAS  Google Scholar 

  6. Hwang TIS, Chen HE, Tsai TF, Lin YC . Combined use of androgen and sildenafil for hypogonadal patients unresponsive to sildenafil alone. Int J Impot Res 2006; 18: 400–404.

    Article  CAS  PubMed  Google Scholar 

  7. Chiang HS, Hwang TIS, Hsui YS, Lin YC, Chen HE, Chen GC et al. Transdermal testosterone gel increases serum testosterone levels in hypogonadal men in Taiwan with improvements is sexual function. Int J Impot Res 2007; 19: 411–417.

    Article  CAS  PubMed  Google Scholar 

  8. Araujo AB, O'Donnell AB, Brambilla DJ, Simpson WB, Longcope C, Matsumoto AM et al. Prevalence and incidence of androgen deficiency in middle-aged and older men: estimates from the Massachusetts Male Aging Study. J Clin Endocrinol Metab 2004; 89: 5920–5926.

    Article  CAS  PubMed  Google Scholar 

  9. Morales A, Lunenfeld B . Investigation, treatment and monitoring of late-onset hypogonadism in males. Official recommendations of ISSAM. International society for the study of the aging male. Aging Male 2002; 5: 151–158.

    Google Scholar 

  10. Lin YC, Hwang TIS, Chiang HS, Yang CR, Wu HC, Wu TL et al. Correlations of androgen deficiency with clinical symptoms in Taiwanese males. Int J Impot Res 2006; 18: 343–347.

    Article  CAS  PubMed  Google Scholar 

  11. Morley JE, Charlton E, Patrick P, Kaiser FE, Cadeau P, McCready D et al. Validation of a screening questionnaire for androgen deficiency in aging males. Metabolism 2000; 49: 1239–1242.

    Article  CAS  PubMed  Google Scholar 

  12. Smith KW, Feldman HA, McKinlay JB . Construction and field validation of a self-administered screener for testosterone deficiency (hypogonadism) in ageing men. Clin Endocrinol (Oxf) 2000; 53: 703–711.

    Article  CAS  Google Scholar 

  13. Christ-Crain M, Mueller B, Gasser TC, Kraenzlin M, Trummler M, Huber P et al. Is there a clinical relevance of partial deficiency of the aging male? J Urol 2004; 172: 624–627.

    Article  CAS  PubMed  Google Scholar 

  14. Chen KK, Chiang HS, Jiann BP, Lin JSN, Liu WJ, Hsieh JT et al. Prevalence of erectile dysfunction and impacts on sexual activity and self-reported intercourse satisfaction in men older than 40 years in Taiwan. Int J Impot Res 2004; 16: 249–255.

    Article  PubMed  Google Scholar 

  15. Donatucci CF, Lue TF . Erectile dysfunction in men under 40: etiology and treatment choice. Int J Impot Res 1993; 5: 97–103.

    CAS  PubMed  Google Scholar 

  16. Hatzichristou D, Hatzimouratidis K, Bekas M, Apostolidis A, Tzortzis V, Yannakoyorgos K . Diagnostic steps in the evaluation of patients with erectile dysfunction. J Urol 2002; 168: 618–620.

    Google Scholar 

  17. Rhoden EL, Teloken C, Sogari PR, Souto CAV . The relationship of serum testosterone to erectile function in normal aging men. J Urol 2002; 167: 1745–1748.

    Article  CAS  PubMed  Google Scholar 

  18. Traish AM, Park K, Dhir V, Kim NN, Moreland RB, Goldstein I . Effects of castration and androgen replacement on erectile function in a rabbit model. Endocrinology 1999; 140: 1861–1868.

    Article  CAS  PubMed  Google Scholar 

  19. Traish AM, Toselli P, Jeong SJ, Kim NN . Adipocyte accumulation in penile corpus cavernosum of the orchidectomized rabbit: a potential mechanism for veno-occlusive dysfunction in androgen deficiency. J Androl 2005; 26: 242–248.

    Article  PubMed  Google Scholar 

  20. Morelli A, Filippi S, Mancina R, Luconi M, Vignozzi L, Marini M et al. Androgens regulate phosphodiesterase type 5 expression and functional activity in corpora cavernosa. Endocrinology 2004; 145: 2253–2263.

    Article  CAS  PubMed  Google Scholar 

  21. Rajfer J, Aronson WJ, Bush PA, Dorey FJ, Ignarro LJ . Nitric oxide as a mediator of relaxation of the corpus cavernosum in response to nonadrenergic, noncholinergic neurotransmission. N Engl J Med 1992; 326: 90–94.

    Article  CAS  PubMed  Google Scholar 

  22. Mills TM, Lewis RW, Stopper VS . Androgenic maintenance of inflow and veno-occlusion during erection in the rat. Biol Reprod 1998; 59: 1413–1418.

    Article  CAS  PubMed  Google Scholar 

  23. Scragg JL, Jones RD, Channer KS, Jones TH, Peers G . Testosterone is a potent inhibitor of 1-type Ca2+ channels. Biochem Biophys Res Commun 2004; 318: 503–506.

    Article  CAS  PubMed  Google Scholar 

  24. Reilly CM, Stopper VS, Mills TM . Androgens modulate the alpha-adrenergic responsiveness of vascular smooth muscle in the corpus cavernosum. J Androl 1997; 18: 26–31.

    CAS  PubMed  Google Scholar 

  25. Rogers RS, Graziottin TM, Lin CM, Kan YW, Lue T . Intracavernosal vascular endothelial growth factor (VEGF) injection and adeno-associated virus-mediated VEGF gene therapy prevent and reverse venogenic erectile dysfunction in rats. Int J Impot Res 2003; 15: 26–27.

    Article  CAS  PubMed  Google Scholar 

  26. Steidle C, Schwartz S, Jacoby K, Sebree T, Smith T, Bachand R . AA2500 testosterone gel normalizes androgen levels in aging males with improvements in body composition and sexual function. J Clin Endocrinol Metab 2003; 88: 2673–2681.

    Article  CAS  PubMed  Google Scholar 

  27. Zitzmann M, Faber S, Nieschlag E . Association of specific symptoms and metabolic risks with serum testosterone in older men. J Clin Endocrinol Metabol 2006; 91: 4335–4343.

    Article  CAS  Google Scholar 

  28. Becker AJ, Uckert S, Stief CG, Truss MC, Machtens S, Scheller F et al. Cavernous and systemic testosterone levels in different phases of human penile erection. Urology 2000; 56: 125–129.

    Article  CAS  PubMed  Google Scholar 

  29. Shabsigh R, Kaufman JM, Steidle C, Padma-Nathan H . Randomized study of testosterone gel as adjunctive therapy to sildenafil in hypogonadal men with erectile dysfunction who do not respond to sildenafil alone. J Urol 2004; 172: 658–663.

    Article  CAS  PubMed  Google Scholar 

  30. Wang C, Swerdloff RS, Iranmanesh A, Dobs A, Snyder PJ, Cunningham G . Transdermal testosterone gel improves sexual function mood, muscle strength, and body composition parameters in hypogonadal men. Testosterone Gel Study Group. J Clin Endocrinol Metab 2000; 85: 2839–2853.

    CAS  PubMed  Google Scholar 

  31. Rhoden EL, Morgentaler A . Testosterone replacement therapy in hypogonadal men at high risk for prostate cancer: results of 1 year of treatment in men with prostatic intraepithelial neoplasia. J Urol 2003; 170(6 Part 1): 2348–2351.

    Article  CAS  PubMed  Google Scholar 

  32. Morales A, Johnston B, Heaton JW, Clark A . Oral androgens in the treatment of hypogonadal impotent men. J Urol 1994; 152: 1115–1118.

    Article  CAS  PubMed  Google Scholar 

  33. Amory JK, Watts NB, Easley KA, Sutton PR, Anawalt BD, Matsumoto AM et al. Exogenous testosterone or testosterone with finasteride increases bone mineral density in older men with low serum testosterone. J Clin Endocrinol Metab 2004; 89: 503–510.

    Article  CAS  PubMed  Google Scholar 

  34. Whitsel EA, Boyko EJ, Matsumoto AM, Anawalt BD, Siscovick DS . Intramuscular testosterone esters and plasma lipids in hypogonadal men: a meta-analysis. Am J Med 2001; 111: 261–269.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Urology, Department of Surgery, Shin Kong WHS Memorial Hospital, Taipei, Taiwan

    T I S Hwang & Y-C Lin

  2. School of Medicine, Fu-Jen Catholic University Taipei, Taipei, Taiwan

    T I S Hwang

  3. School of Medicine, Taipei Medical University, Taipei, Taiwan

    T I S Hwang

Authors
  1. T I S Hwang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Y-C Lin
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to T I S Hwang.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hwang, T., Lin, YC. The relationship between hypogonadism and erectile dysfunction. Int J Impot Res 20, 231–235 (2008). https://doi.org/10.1038/sj.ijir.3901633

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.ijir.3901633

Keywords

This article is cited by

Search

Advanced search

Quick links